Skip to main content

Featured

Carney Tempers Expectations on U.S.-Canada Trade Talks

                                             Carney says U.S. tariff reprieve 'unlikely' to happen before CUSMA review talks. Canadian Prime Minister Mark Carney has downplayed the likelihood of a near-term trade deal between Canada and the United States, signaling that any progress will likely be folded into the upcoming review of the Canada-U.S.-Mexico Agreement (CUSMA) scheduled for 2026. Speaking at a press conference in Ottawa, Carney explained that efforts to secure sector-specific agreements—particularly in industries such as steel, aluminum, autos, and lumber—have stalled since U.S. President Donald Trump abruptly ended negotiations in October. The talks were derailed after Ontario aired a controversial anti-tariff advertisement featuring former President Ronald Reagan, which drew sharp criticism from Washington. Carney emphasized that while Canada...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment